Trametinib (Mekinist)

Indicated for unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA.

Not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.

2 mg orally once daily, to be taken at least 1 hour before or 2 hours after a meal.

Duration of therapy: Until disease progression or unacceptable toxicity occurs.

As a single agent, overall response rate 54% with a median duration of response of 5.6 months for metastatic melanoma.

In combination with dabrafenib, overall response rate 76% with a median duration of response of 10.5 months in metastatic melanoma.

Leave a Reply

Your email address will not be published. Required fields are marked *